MISSISSAUGA, Ontario, Aug. 14, 2025 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) will be reporting its financial results for the three months and six months ended June 30, 2025 on Thursday, August 21, 2025 after market hours. A presentation on the Company’s second quarter and first half 2025 results by René Goehrum, BioSyent President and CEO, will also be available on the Company’s website on the date of release. About BioSyent Inc. Listed on the TSX Venture Exchange under ...

Financial Performance - BioSyent Inc. reported a total company sales of CAD 10,978,960 for Q1 2025, representing a 42% increase compared to Q1 2024 [1][7] - Canadian Pharma sales reached CAD 9,159,652, up 21% year-over-year, while International Pharma sales surged by 135% to CAD 1,535,216 [1][7] - EBITDA for Q1 2025 was CAD 3,201,647, reflecting a 45% increase from the previous year, with a consistent EBITDA margin of 29% [1][7] - Net Income After Taxes (NIAT) was CAD 2,319,933, a 31% increase compared to Q1 2024, with a fully diluted EPS of CAD 0.20, up 35% [1][7] Product Performance - FeraMAX Pd sales grew by 18% in Q1 2025, bolstered by its recognition as the 1 recommended OTC oral iron supplement in Canada for the tenth consecutive year [2] - Tibella (tibolone) product sales increased by 53% in Canada, with improved gross margins following the acquisition of worldwide rights in September 2024 [2] - The first international shipments of Tibelia generated new revenues of CAD 0.8 million in Q1 2025, with further deliveries planned throughout the year [2] Corporate Developments - Mr. Prakash Gowd was elected to the Board of Directors, replacing Mr. Larry Andrews, who retired after seven years of service [2] - The company repurchased 19,500 common shares under its Normal Course Issuer Bid (NCIB) during Q1 2025 [3] - A quarterly cash dividend of CAD 0.05 per common share was paid on March 14, 2025, with a subsequent dividend declared for June 13, 2025 [3] Financial Position - As of March 31, 2025, total assets increased to CAD 42,762,182, a 3% rise from December 31, 2024 [8][9] - Current assets rose by 17% to CAD 28,642,114, driven by an 87% increase in trade and other receivables [8][9] - Total equity also grew by 3% to CAD 36,011,796, indicating a stable financial position [8][9]

MISSISSAUGA, Ontario, May 15, 2025 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce that its Board of Directors has declared a quarterly dividend of $0.05 per common share, payable in Canadian Dollars on June 13, 2025, to shareholders of record at the close of business on May 30, 2025. This second quarter 2025 dividend compares with the first quarter 2025 dividend of $0.05 per common share. This dividend qualifies as an 'eligible dividend' for Canadian in ...

MISSISSAUGA, Ontario, May 08, 2025 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) will be reporting its financial results for the three months ended March 31, 2025 on Thursday, May 15, 2025 after market hours. A presentation on the Company’s first quarter 2025 results by René Goehrum, BioSyent President and CEO, will also be available on the Company’s website on the date of release. About BioSyent Inc. Listed on the TSX Venture Exchange under the trading symbol “RX”, BioSyent ...

Group 1 - BioSyent Inc. will present at the 2025 Bloom Burton & Co. Healthcare Investor Conference in Toronto on May 5 and 6, 2025 [1] - Mr. René Goehrum, President and CEO, will provide an overview of the company's business and corporate activities on May 5 at 11:30am EDT [1] - One-on-one meetings with Mr. Goehrum can be scheduled by registered attendees through the conference portal [2] Group 2 - BioSyent is a profitable growth-oriented specialty pharmaceutical company focused on in-licensing or acquiring innovative healthcare products [3] - The company supports healthcare professionals by marketing its products through community, specialty, and international business units [3] - As of the press release date, BioSyent has 11,254,638 common shares outstanding [4]

Company Overview - BioSyent Inc. is a profitable growth-oriented specialty pharmaceutical company listed on the TSX Venture Exchange under the symbol "RX" [3] - The company focuses on in-licensing or acquiring innovative pharmaceutical and healthcare products that are safe, effective, and have a proven track record of improving patient lives [3] Upcoming Conference Participation - BioSyent will attend the Planet MicroCap Showcase: VEGAS 2025 investor conference in Las Vegas from April 22 to April 24, 2025 [1] - Mr. René Goehrum, President and CEO, will present at the conference on April 23 from 12:30pm to 1:00pm PDT in Track 2 – Bordeaux [1] - One-on-one meetings with investors will be available on April 23 from 1:30pm to 6:00pm PDT and on April 24 from 8:00am to 5:00pm PDT [2] Share Information - As of the date of the press release, BioSyent has 11,254,638 common shares outstanding [4]